Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. - Basheer F; Giotopoulos G; Meduri E; Yun H; Mazan M; Sasca D; Gallipoli P; Marando L; Gozdecka M; Asby R; Sheppard O; Dudek M; et al. (The Journal of experimental medicine, 2019)